DAYTON, Ohio–(BUSINESS WIRE)–MedsEngine LLC is a clinical decision support company that develops software for treating chronic disease. Data was presented on cerebrovascular events and myocardial infarctions in patients treated with MedsEngine-Hypertension at the 2024 European Society of Cardiology Congress in London, U.K.
Hypertension is recognized as a leading cause of atherosclerotic cardiovascular disease and death globally. Data was retrieved from EHRs for a period of seven years for patients with hypertension managed with MedsEngine (average age 61) and patients with normal blood pressure (average age 43). Comparable cerebrovascular and MI events were observed (10/1000 and 4.2/1000 patients, respectively). This observation is noteworthy as it suggests controlling hypertension reduces strokes and MIs to the rate of a non-hypertensive 43-year-old.
Dr. Doug Romer, COO/CMO of MedsEngine, stated, “Utilizing MedsEngine-Hypertension, that incorporates hemodynamic data and a proprietary algorithm to control hypertension, can have a positive impact on the occurrence of strokes and heart disease. MedsEngine has demonstrated blood pressure control rates of 92% (<140/90) for 10 consecutive years.”
MedsEngine will have a booth at the AHA Hypertension Scientific Session in Chicago from September 5-8. Stop by to learn more about the benefits of MedsEngine.
About MedsEngine
MedsEngine develops EHR-integrated clinical decision support applications that generate real-time, personalized, evidence-based medication recommendations for Hypertension, Cholesterol Management, Type 2 Diabetes, and Heart Failure. For more information, visit http://www.medsengine.com.
Contacts
01
From telecom veteran to Dutch Startup Visa success: The Jignesh Dave story